Anchor Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Anchor Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.02M	Buy	3,389 +570	+20%	+$172K	0.08%	188
2026 Q1	$933K	Buy	2,819 +124	+5%	+$42.2K	0.08%	202
2025 Q4	$1.07M	Buy	2,695 +446	+20%	+$197K	0.09%	190
2025 Q3	$1.03M	Buy	2,249 +2,049	+1,025%	+$834K	0.08%	191
2025 Q2	$65.2K	Hold	200	–	–	0.01%	543
2025 Q1	$54K	Hold	200	–	–	0.01%	555
2024 Q4	$47.1K	Hold	200	–	–	﹤0.01%	582
2024 Q3	$55K	Hold	200	–	–	0.01%	551
2024 Q2	$48.6K	Hold	200	–	–	0.01%	523
2024 Q1	$29.9K	Hold	200	–	–	﹤0.01%	614
2023 Q4	$38.3K	Hold	200	–	–	﹤0.01%	557
2023 Q3	$35.4K	Hold	200	–	–	﹤0.01%	559
2023 Q2	$38K	Hold	200	–	–	﹤0.01%	549
2023 Q1	$40.1K	Hold	200	–	–	0.01%	559
2022 Q4	$47.5K	Hold	200	–	–	0.01%	531
2022 Q3	$40K	Hold	200	–	–	0.01%	542
2022 Q2	$29.2K	Hold	200	–	–	﹤0.01%	597
2022 Q1	$32.7K	Hold	200	–	–	﹤0.01%	601
2021 Q4	$33.9K	Hold	200	–	–	﹤0.01%	616
2021 Q3	$37.8K	Hold	200	–	–	0.01%	558
2021 Q2	$33.9K	Hold	200	–	–	﹤0.01%	580
2021 Q1	$28.2K	Hold	200	–	–	﹤0.01%	584
2020 Q4	$26K	Hold	200	–	–	﹤0.01%	562
2020 Q3	$29.1K	Hold	200	–	–	0.01%	516
2020 Q2	$29.6K	Hold	200	–	–	0.01%	503
2020 Q1	$21.8K	Hold	200	–	–	0.01%	523
2019 Q4	$23K	Hold	200	–	–	﹤0.01%	552
2019 Q3	$16.1K	Hold	200	–	–	﹤0.01%	589
2019 Q2	$14.5K	Hold	200	–	–	﹤0.01%	600
2019 Q1	$18.7K	Hold	200	–	–	﹤0.01%	564
2018 Q4	$14.6K	Hold	200	–	–	﹤0.01%	577
2018 Q3	$17.5K	Hold	200	–	–	﹤0.01%	582
2018 Q2	$19.7K	Hold	200	–	–	﹤0.01%	582
2018 Q1	$23.8K	Hold	200	–	–	0.01%	555
2017 Q4	$25.4K	Buy	+200	New	+$25.1K	0.01%	544

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Anchor Investment Management's ALNY Position: Q2 2026 in Review

Anchor Investment Management increased its Alnylam Pharmaceuticals (ALNY) stake by 20% in Q2 2026, buying an estimated $172K and bringing the position to 3,389 shares worth $1.02M. The position accounts for 0.08% of the portfolio, ranked #188.

Anchor Investment Management first reported a position in ALNY in Q4 2017 and has held it in 35 quarters since. The position peaked at $1.07M in Q4 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Anchor Investment Management held 3,389 shares of Alnylam Pharmaceuticals worth $1.02M as of Q2 2026.
Anchor Investment Management bought 570 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $172K.
Alnylam Pharmaceuticals made up 0.08% of Anchor Investment Management's portfolio in Q2 2026, its #188 holding.
Anchor Investment Management first reported a position in Alnylam Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
Anchor Investment Management's Alnylam Pharmaceuticals position peaked at $1.07M in Q4 2025.
791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Anchor Investment Management's 13F filing for Q2 2026, filed 15 Sep 2026.